These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 20684669)

  • 1. Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin.
    Kirson NY; Ivanova JI; Birnbaum HG; Wei R; Kantor E; Puenpatom RA; Ben-Joseph RH; Summers KH
    J Med Econ; 2010; 13(3):482-91. PubMed ID: 20684669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of a new 8% capsaicin patch compared to existing therapies for postherpetic neuralgia.
    Armstrong EP; Malone DC; McCarberg B; Panarites CJ; Pham SV
    Curr Med Res Opin; 2011 May; 27(5):939-50. PubMed ID: 21375358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings.
    Gore M; Sadosky A; Tai KS; Stacey B
    Clin Ther; 2007 Aug; 29(8):1655-70. PubMed ID: 17919547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective.
    Tarride JE; Gordon A; Vera-Llonch M; Dukes E; Rousseau C
    Clin Ther; 2006 Nov; 28(11):1922-34. PubMed ID: 17213013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of a lidocaine 5% medicated plaster relative to gabapentin for postherpetic neuralgia in the United Kingdom.
    Dakin H; Nuijten M; Liedgens H; Nautrup BP
    Clin Ther; 2007 Jul; 29(7):1491-507. PubMed ID: 17825701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective.
    Liedgens H; Hertel N; Gabriel A; Nuijten M; Dakin H; Mitchell S; Nautrup BP
    Clin Drug Investig; 2008; 28(9):583-601. PubMed ID: 18666805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Descriptive analysis of Medicaid patients with postherpetic neuralgia treated with lidocaine patch 5%.
    Kirson NY; Ivanova JI; Birnbaum HG; Wei R; Kantor E; Amy Puenpatom R; Ben-Joseph RH; Summers KH
    J Med Econ; 2010; 13(3):472-81. PubMed ID: 20684670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world treatment of post-herpetic neuralgia with gabapentin or pregabalin.
    Johnson P; Becker L; Halpern R; Sweeney M
    Clin Drug Investig; 2013 Jan; 33(1):35-44. PubMed ID: 23179473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia.
    O'Connor AB; Noyes K; Holloway RG
    J Am Geriatr Soc; 2007 Aug; 55(8):1176-84. PubMed ID: 17661955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy.
    Udall M; Harnett J; Mardekian J
    J Med Econ; 2012; 15(2):361-70. PubMed ID: 22181052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: Findings from a cost-consequences analysis in a nested case-control study.
    Pérez C; Navarro A; Saldaña MT; Masramón X; Rejas J
    Clin Ther; 2010 Jul; 32(7):1357-70. PubMed ID: 20678683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis.
    Ritchie M; Liedgens H; Nuijten M
    Clin Drug Investig; 2010; 30(2):71-87. PubMed ID: 20067326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost analysis of adding pregabalin or gabapentin to the management of community-treated patients with peripheral neuropathic pain.
    Sicras-Mainar A; Rejas-Gutiérrez J; Navarro-Artieda R; Planas-Comes A
    J Eval Clin Pract; 2012 Dec; 18(6):1170-9. PubMed ID: 21883712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans.
    Margolis JM; Cao Z; Onukwugha E; Sanchez RJ; Alvir J; Joshi AV; Mullins CD
    Am J Manag Care; 2010 Jun; 16(6):447-56. PubMed ID: 20560688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Patterns and Medication Use in Patients with Postherpetic Neuralgia.
    Gudin J; Fudin J; Wang E; Haylon T; Patel K; Goss TF
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1387-1396. PubMed ID: 31589557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of a step-therapy protocol for pregabalin on healthcare utilization and expenditures in a commercial population.
    Udall M; Louder A; Suehs BT; Cappelleri JC; Joshi AV; Patel NC
    J Med Econ; 2013; 16(6):784-92. PubMed ID: 23565813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Costs and health resources utilization following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain: a post hoc analysis.
    Navarro A; Saldaña MT; Pérez C; Masramón X; Rejas J
    Pain Pract; 2012 Jun; 12(5):382-93. PubMed ID: 22004531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study.
    Baron R; Mayoral V; Leijon G; Binder A; Steigerwald I; Serpell M
    Curr Med Res Opin; 2009 Jul; 25(7):1663-76. PubMed ID: 19485723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics, pharmacotherapy and healthcare resource use among patients with fibromyalgia newly prescribed gabapentin or pregabalin.
    Gore M; Sadosky AB; Zlateva G; Clauw DJ
    Pain Pract; 2009; 9(5):363-74. PubMed ID: 19500273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics, pharmacotherapy, and healthcare resource use among patients with diabetic neuropathy newly prescribed pregabalin or gabapentin.
    Gore M; Tai KS; Zlateva G; Bala Chandran A; Leslie D
    Pain Pract; 2011; 11(6):528-39. PubMed ID: 21435162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.